Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Enzalutamide
Drug ID BADD_D00775
Description Enzalutamide is an androgen receptor inhibitor for the treatment of castration-resistant prostate cancer. FDA approved on August 31, 2012.
Indications and Usage Enzalutamide is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.
Marketing Status Prescription
ATC Code L02BB04
DrugBank ID DB08899
KEGG ID D10218
MeSH ID C540278
PubChem ID 15951529
TTD Drug ID D0QK5X
NDC Product Code 54893-0044; 55111-976; 0469-0625; 65392-2209; 68554-0106; 65015-876; 62128-0388; 65129-1376; 59285-018; 42385-733; 0469-0725; 11014-0003; 15308-1121; 0469-0125
Synonyms enzalutamide | 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-benzamide | enzalutamide D3 | HC-1119 | HC 1119 | 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-(methyl-d3)benzamide | Xtandi | MDV 3100 | MDV3100 | MDV-3100
Chemical Information
Molecular Formula C21H16F4N4O2S
CAS Registry Number 915087-33-1
SMILES CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Liver function test increased13.03.01.044--Not Available
Cerebellar haemorrhage24.07.04.023; 17.08.01.0460.000384%Not Available
Full blood count decreased13.01.07.004--Not Available
Jaw fracture15.08.02.006; 12.04.05.0010.002942%Not Available
Malignant pleural effusion16.32.03.014; 22.05.04.0010.000576%Not Available
Metastases to bone16.22.02.005; 15.09.03.0060.006907%Not Available
Metastases to lymph nodes16.22.02.006; 01.09.01.0150.000576%Not Available
Normal pressure hydrocephalus17.07.01.0020.000384%Not Available
Sternal fracture15.08.07.002; 12.04.07.0020.001471%Not Available
Tracheal obstruction12.01.03.007; 22.04.07.0060.001471%
Urinary bladder haemorrhage24.07.01.086; 20.03.01.0230.002942%Not Available
Urinary tract infection enterococcal20.08.02.007; 11.02.08.0030.001471%Not Available
Terminal state08.01.03.0790.004413%Not Available
Fear of falling19.06.03.0080.001471%Not Available
Lumbar vertebral fracture12.04.04.007; 15.08.05.0070.001471%Not Available
Laziness19.04.04.0050.001471%Not Available
Metastases to meninges17.02.10.012; 16.22.02.0030.000576%Not Available
Clostridium difficile infection11.02.02.009--Not Available
Prostatic specific antigen abnormal13.22.01.0150.005884%Not Available
General physical condition abnormal13.15.01.0400.002206%Not Available
Culture positive13.08.02.0030.001471%Not Available
Scan abnormal13.18.03.0050.001471%Not Available
Foaming at mouth17.02.05.056; 08.01.03.070; 07.05.05.0190.001471%Not Available
Bladder tamponade24.07.01.064; 20.02.02.0240.001471%Not Available
Hormone-refractory prostate cancer21.04.02.007; 16.25.01.0040.002111%Not Available
Stress cardiomyopathy02.04.01.012; 24.04.04.026--Not Available
Quality of life decreased13.18.01.0130.002942%Not Available
Oncologic complication16.32.03.0250.000384%Not Available
Exposed bone in jaw15.02.04.034--Not Available
Seizure like phenomena17.12.03.0300.001471%Not Available
The 22th Page    First    Pre   22 23    Next   Last    Total 23 Pages